Navigation Links
New Treatments Emerging from Immune and Inflammatory Disease R&D Pipelines
Date:6/19/2012

New York, NY (PRWEB) June 19, 2012

A new syndicated TrendsmemeTM Report: Immune and Inflammatory Diseases has been released by Medmeme, LLC., a global leader in comprehensive, integrated medical and science information database platforms. The report details the trends and potential for drug developers in immune/inflammatory diseases particularly focusing on three key disease indications: RA (rheumatoid arthritis), IBD (inflammatory bowel disease), and SLE (systemic lupus erythematosus). According to the Centers for Disease Control and Prevention (CDC) and the Arthritis Foundation (AF), between 1.3 million and 1.5 million people in the United States have RA. The CDC also reports than mortality rates among RA patients are nearly 2.5 times higher than those in the general population, owing primarily to excess risk of cardiovascular disease, infections, and some cancers. The Medmeme report illustrates that treatment of these three indications commands much of the R&D effort and market in this therapeutic category and represents recent, notable scientific progress. R&D for the three indications also offers a window into issues that are relevant broadly across the category.

Medmeme CEO Mahesh Naithani describes the marketplace: ”The value of the immune/inflammatory disease pharmaceutical markets has been driven by very intense research to characterize pathological factors, which was then translated into development of highly targeted biological therapies. Commercial success has come to the companies and brands that have contributed to this clinical revolution. Just three drugs in this therapeutic area— Amgen/Pfizer’s Enbrel, Johnson & Johnson’s Remicade, and Abbott’s Humira— respectively were the seventh, eighth, and ninth highest selling pharmaceutical brands worldwide in 2010, with combined sales exceeding $18 billion. Need for new treatments and market potential have encouraged many companies to be active such as Roche, Merck, Biogen Idec, AstraZeneca, Eli Lilly, Novartis, Regeneron, GlaxoSmithKline, Astellas, and Sanofi, others too. Another major driver of success in immune/inflammatory disease markets has been company strategies of label expansion into multiple disease areas, particularly for biologics like the TNF-a inhibitors.”

Scientific data from the Medmeme database shows that discussion centering on late-stage RA emerging therapies in medical conference presentations and journal publications increased in 2011. This increase is primarily attributable to novel non-TNF-alpha target drugs such as: AstraZeneca’s fostamatinib, an oral Syk kinase inhibitor, Novartis’s secukinumab, a monoclonal antibody against IL-17A, and Pfizer’s tofacitinib, an oral JAK inhibitor. Of these three frontrunner emerging therapies, Pfizer’s tofacitinib may reach market this year. The drug was submitted for U.S. approval to treat RA at the end of 2011.

The syndicated TrendsmemeTM Report: Immune and Inflammatory Diseases can be purchased separately, or, along with other MedMeme reports in the new series, at discounted pricing. To learn more, contact us, or see our website, http://www.medmeme.com/products/syndicated-reports/reports/trendsmeme-reports.

Medmeme, LLC                                     
Yan Barshay, Executive Vice President                 
+1 212-725-5992                                             
yan(at)medmeme(dot)com    
            or
Ray Wright, Vice President, Sales
+ 1 508-278-4595
rwright(at)medmeme(dot)com

Read the full story at http://www.prweb.com/releases/2012/6/prweb9616233.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Feelings of immaturity accompany alcohol misuse into adulthood; discovery could improve treatments
2. Research May Point to New Obesity Treatments
3. Researchers make promising discovery in pursuit of effective lymphoma treatments
4. Study examines treatments for relieving breathing difficulties among patients with lung effusions
5. LA BioMeds Dr. Patricia Dickson researching treatments for neurodegenerative disorders
6. Pre-op Treatments Boost Survival for Esophageal Cancer Patients: Study
7. 1960s-era anti-cancer drug points to treatments for Lou Gehrigs disease
8. Rejuv Medical In Sartell, MN Now Offering Stem Cell Treatments
9. MDS researchers join forces to advance patient treatments and outcomes
10. How does the immune system fight off threats to the brain? New research yields fresh insight
11. Regulatory immune cell diversity tempers autoimmunity in rheumatoid arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology: